本帖最后由 老马 于 2013-3-13 13:43 编辑 2 A& `& ^: R# M" U n) u& T6 O& u
1 b* }1 q) W9 Q* \4 n; L9 U% ~
健择（吉西他滨）+顺铂+阿瓦斯汀
- g! C; f. c: a6 Z }. k, d Gemzar +Cisplatin + Avastin
: _' ]8 b s9 n# w+ Shttp://annonc.oxfordjournals.org/content/21/9/1804.full7 |" y# x8 v/ ?
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 8 R0 q! `. c* C# w" r* G8 f
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
, b1 ~( \4 U. y. @/ _6 k/ \Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. D6 ?0 B$ }* C& ]8 d G' h$ J
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1141)
9 |1 ~% C1 x0 r+ A6 E5 T华为网盘附件：' Y# E+ G Y+ L7 M, m$ y. s
【华为网盘】ava.JPG
+ C# {% }* q7 I. }" P9 S2 K |
11011102001537 )
显身卡
